Business
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D
LYON, France, July 25, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/aa125bbccd20e6c937645cc8f30df45d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KjVMo7319X_0WbaNAXvGog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/aa125bbccd20e6c937645cc8f30df45d","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Gh0ABLnl6cB3CHe3XIyzxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/aa125bbccd20e6c937645cc8f30df45d","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"This Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection) conducted in China in people with Type 2 diabetes, successfully demonstrated, in comparison with standard of care Humalog®:","length":196,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Non inferior HbA1c reduction at 26 weeks (primary endpoint)","length":59,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant reduction of the rise of blood glucose after a test meal (key secondary endpoints)","length":94,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":153,"olType":false}]},{"val":[{"type":"text","content":"Mean blood glucose level over the day monitored by 10-point SMBG, an important supportive endpoint, was also significantly decreased, in comparison with Humalog®","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A series of prespecified subgroup analyses in HbA1c fully support the benefit of the product in long term blood glucose control","length":127,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":637,"olType":false},{"type":"text","content":"LYON, France, July 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":62,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive ...